Cancer Immunotherapy at the Crossroads

1. Front Matter

   Pages i-xvii

   PDF

2. Basic Mechanisms of Immune Evasion

   1. Front Matter

      Pages 1-1

      PDF

   2. HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape

      • Michael Campoli, Chien-Chung Chang, Xin-Hui Wang, Soldano Ferrone

      Pages 3-34

   3. Immune Defects in T Cells From Cancer Patients

      • Augusto C. Ochoa, Paulo C. Rodriguez, Jovanny Zabaleta, Pelayo Correa, Arnold H. Zea

      Pages 35-48

   4. Malfunction of the Dendritic Cell System in Cancer

      • Zoya R. Yurkovetsky, Irina L. Tourkova, Levent Balkir, Lori Perez, Galina V. Shurin, Gurkamal S. Chatta et al.

      Pages 49-65

   5. CD4+ T-Cell-Mediated Immunity to Cancer

      • Tomohide Tatsumi, Amy Wesa, James H. Finke, Ronald M. Bukowski, Walter J. Storkus

      Pages 67-86

   6. Immunological Ignorance in Cancer

      • Koji Tamada, Lieping Chen

      Pages 87-99

   7. The Role of Receptor-Mediated Apoptosis in T-Cell Dysfunction

      • Hannah Rabinowich, Brian R. Gastman

      Pages 101-117

   8. Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis

      • Ithaar H. Derweesh, Luis Molto, Charles Tannenbaum, Patricia Rayman, Christina Moon, Cynthia Combs et al.

      Pages 119-144

   9. The Role of Tumor Gangliosides in the Immune Dysfunction of Cancer

      • Stephan Ladisch

      Pages 145-156

   10. Interleukin-10-Induced Immune Suppression in Cancer

       • Arvin S. Yang, Edmund C. Lattime

       Pages 157-172

   11. Accentuating Tumor Immunity Through Costimulation

       • Andrew D. Weinberg, Dean E. Evans, Arthur A. Hurwitz

       Pages 173-194

   12. Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion

       • Peter A. Cohen, Gregory E. Plautz, James H. Finke, Suyu Shu

       Pages 195-213

   13. Tumor Resistance to Apoptosis

       • Robert G. Uzzo, Paul Cairns, Nickolai Dulin, Eric M. Horwitz, Alan Pollack, Vladimir Kolenko

       Pages 215-234

3. Clinical Relevance of Immune Evasion

   1. Front Matter

      Pages 235-235

      PDF

   2. The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines

      • Ena Wang, Francesco M. Marincola

      Pages 237-255

   3. Altered Signaling in T Lymphocytes of Patients With Cancer

      • Theresa L. Whiteside

      Pages 257-277

   4. Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma

      • Richard W. Childs, Cristian A. Carvallo

      Pages 279-293

   5. Immune Defects in Patients Suffering From Non-Hodgkin’s Lymphoma

      • Thomas Zander, Daniel Re, Michael von Bergwelt-Baildon, Jürgen Wolf, Joachim L. Schultze

      Pages 295-314

   6. Immune Dysfunction in Classical Hodgkin’s Lymphoma

      • Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg, Sibrand Poppema

      Pages 315-334

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

• apoptosis
• brain tumors
• carcinoma
• cell
• immunotherapy
• lymphocytes
• lymphoma
• renal cell carcinoma
• transplantation
• tumor

"...good reading for all those interested in oncological immunotherapy." -Cancer Forum

"State of the art and insightful...illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors." - Tumori

• Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA

  James H. Finke

• Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, USA

  Ronald M. Bukowski

Policies and ethics